Log in

NASDAQ:NTGNNeon Therapeutics Stock Price, Forecast & News

$3.07
0.00 (0.00 %)
(As of 05/6/2020)
Add
Compare
Today's Range
$3.07
Now: $3.07
$3.07
50-Day Range
$2.22
MA: $2.93
$3.09
52-Week Range
$0.88
Now: $3.07
$6.25
VolumeN/A
Average Volume516,108 shs
Market Capitalization$88.93 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.81
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Neon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTGN
CUSIPN/A
CIKN/A
Phone617-337-4701

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.50 per share

Profitability

Net Income$-79,780,000.00

Miscellaneous

Employees102
Market Cap$88.93 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive NTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for NTGN and its competitors with MarketBeat's FREE daily newsletter.

Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions

How has Neon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Neon Therapeutics' stock was trading at $1.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NTGN shares have increased by 93.1% and is now trading at $3.07. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neon Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Neon Therapeutics.

When is Neon Therapeutics' next earnings date?

Neon Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Neon Therapeutics.

How were Neon Therapeutics' earnings last quarter?

Neon Therapeutics Inc (NASDAQ:NTGN) released its quarterly earnings results on Monday, March, 2nd. The company reported ($0.63) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.66) by $0.03. View Neon Therapeutics' earnings history.

What price target have analysts set for NTGN?

5 analysts have issued twelve-month price objectives for Neon Therapeutics' stock. Their forecasts range from $2.18 to $15.00. On average, they expect Neon Therapeutics' share price to reach $9.05 in the next twelve months. This suggests a possible upside of 194.6% from the stock's current price. View analysts' price targets for Neon Therapeutics.

Has Neon Therapeutics been receiving favorable news coverage?

Media stories about NTGN stock have been trending neutral recently, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neon Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutNeon Therapeutics.

Are investors shorting Neon Therapeutics?

Neon Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 743,900 shares, an increase of 15.4% from the April 15th total of 644,800 shares. Based on an average trading volume of 449,800 shares, the short-interest ratio is presently 1.7 days. Approximately 4.9% of the shares of the company are short sold. View Neon Therapeutics' Current Options Chain.

Who are some of Neon Therapeutics' key competitors?

What other stocks do shareholders of Neon Therapeutics own?

Who are Neon Therapeutics' key executives?

Neon Therapeutics' management team includes the following people:
  • Mr. Hugh O'Dowd, Pres, CEO & Director (Age 54)
  • Dr. Eric S. Lander, Founder & Director (Age 62)
  • Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 37)
  • Dr. Richard Gaynor, Pres of R&D (Age 69)
  • Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer

When did Neon Therapeutics IPO?

(NTGN) raised $101 million in an initial public offering (IPO) on Wednesday, June 27th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Neon Therapeutics' stock symbol?

Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN."

Who are Neon Therapeutics' major shareholders?

Neon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.85%), Athanor Capital LP (1.89%), Maven Securities LTD (1.32%), State Street Corp (0.95%), Geode Capital Management LLC (0.73%) and Moneta Group Investment Advisors LLC (0.35%). Company insiders that own Neon Therapeutics stock include Access Industries Holdings Llc and Richard Gaynor. View institutional ownership trends for Neon Therapeutics.

Which major investors are selling Neon Therapeutics stock?

NTGN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, UBS Group AG, and Deutsche Bank AG. Company insiders that have sold Neon Therapeutics company stock in the last year include Access Industries Holdings Llc, and Richard Gaynor. View insider buying and selling activity for Neon Therapeutics.

Which major investors are buying Neon Therapeutics stock?

NTGN stock was bought by a variety of institutional investors in the last quarter, including Athanor Capital LP, Maven Securities LTD, Moneta Group Investment Advisors LLC, State Street Corp, Geode Capital Management LLC, Terril Brothers Inc., Nuveen Asset Management LLC, and Acadian Asset Management LLC. View insider buying and selling activity for Neon Therapeutics.

How do I buy shares of Neon Therapeutics?

Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neon Therapeutics' stock price today?

One share of NTGN stock can currently be purchased for approximately $3.07.

How big of a company is Neon Therapeutics?

Neon Therapeutics has a market capitalization of $88.93 million. The company earns $-79,780,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe.

What is Neon Therapeutics' official website?

The official website for Neon Therapeutics is www.neontherapeutics.com.

How can I contact Neon Therapeutics?

Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.